Page last updated: 2024-12-09

2-(2-methyl-1H-indol-3-yl)ethanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(2-methyl-1H-indol-3-yl)ethanol: A Promising Compound for Research

**2-(2-methyl-1H-indol-3-yl)ethanol**, often abbreviated as **2-Me-TrpOH**, is an organic compound with a complex structure. It is a derivative of **tryptophan**, an essential amino acid, and shares some similarities with the neurotransmitter **serotonin**.

**Importance in Research:**

2-Me-TrpOH is attracting significant research interest due to its potential applications in various fields, including:

* **Neurology:**
* **Antidepressant activity:** Studies suggest that 2-Me-TrpOH might possess antidepressant properties by modulating serotonin pathways.
* **Neuroprotective effects:** Research indicates potential for 2-Me-TrpOH to protect neurons from damage, particularly in conditions like Parkinson's disease.
* **Modulation of cognitive function:** The compound could potentially improve cognitive performance by influencing neurotransmission in the brain.

* **Cancer Research:**
* **Anti-tumor activity:** 2-Me-TrpOH has shown promising results in preclinical studies for treating certain types of cancer by inhibiting tumor growth and promoting apoptosis (cell death).
* **Anti-angiogenesis:** The compound may suppress the formation of new blood vessels that nourish tumors, thus limiting their growth and spread.

* **Other potential applications:**
* **Anti-inflammatory effects:** 2-Me-TrpOH might exhibit anti-inflammatory properties, potentially beneficial for treating conditions like arthritis.
* **Anti-microbial activity:** Research suggests that the compound could possess antibacterial and antifungal properties.

**Current Research Status:**

While 2-Me-TrpOH shows significant promise, most research is still in preclinical stages. Further studies are needed to understand its mechanisms of action, efficacy, and safety in humans.

**Challenges and Future Directions:**

* **Pharmacokinetic profile:** Understanding how 2-Me-TrpOH is absorbed, distributed, metabolized, and excreted in the body is crucial for developing safe and effective treatments.
* **Toxicity and side effects:** Thorough evaluation of potential adverse effects is necessary before human trials.
* **Clinical trials:** Conducting well-designed clinical trials is essential to confirm the efficacy and safety of 2-Me-TrpOH for specific conditions.

**Conclusion:**

2-(2-methyl-1H-indol-3-yl)ethanol is a molecule with exciting potential for various therapeutic applications. Continued research efforts are necessary to translate its promising preclinical results into safe and effective treatments for human diseases.

Cross-References

ID SourceID
PubMed CID659192
CHEMBL ID1430198
CHEBI ID111279
SCHEMBL ID7844388

Synonyms (18)

Synonym
smr000040249
MLS000079794
CHEBI:111279
2-(2-methyl-1h-indol-3-yl)ethanol
HMS2159O08
56895-60-4
1h-indole-3-ethanol, 2-methyl-
HMS3353K19
AKOS022534000
SCHEMBL7844388
CHEMBL1430198
Q27190896
DTXSID00349744
FT-0750857
EN300-3186932
STL570364
2-(2-methyl-1h-indol-3-yl)ethan-1-ol
CS-0246182
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency8.91250.044717.8581100.0000AID485341
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.16230.001318.074339.8107AID926; AID938
huntingtin isoform 2Homo sapiens (human)Potency3.16230.000618.41981,122.0200AID1688
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]